You are here

Telcyta Receives Fast Track Designation as Third Line Treatment in Non-Small Cell Lung Cancer

PALO ALTO, Calif., Dec. 2 /PRNewswire-FirstCall/ -- Telik, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for TELCYTA™ (TLK286) for third line therapy for locally advanced or metastatic non-small cell lung cancer. The FDA previously granted Fast Track designation for TELCYTA™ for third line therapy in patients with platinum refractory or resistant ovarian cancer.

Fast Track programs are designed to facilitate the development and expedite the review of new drugs that demonstrate the potential to treat serious or life-threatening conditions and address unmet medical needs.

Lung cancer results in 28% of all cancer deaths in the U.S., and it is the leading cause of cancer deaths, according to the American Cancer Society (ACS). The ACS estimates that 171,900 new cases of lung cancer will be diagnosed in 2003 and an estimated 157,200 deaths will result from the disease.

Source: Telik, Inc.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs